To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008
Conditions: Healthy Adult Interventions: Drug: SGLT2 inhibitor Sponsors: Jeil Pharmaceutical Co., Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 12, 2023 Category: Research Source Type: clinical trials
SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease
Conditions: Lupus Nephritis; Chronic Kidney Diseases Interventions: Drug: Dapagliflozin 10mg Tab; Drug: Standard maintenance therapy Sponsors: The University of Hong Kong Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 4, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of SGLT2 Inhibitor Therapy in Overweight and Obese Subjects With Cystic Fibrosis-related Diabetes: a Pilot Study
Conditions: Cystic Fibrosis-related Diabetes; Cystic Fibrosis Interventions: Drug: Empagliflozin; Other: Placebo Control Sponsors: Amir Moheet Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2023 Category: Research Source Type: clinical trials
Impact of SGLT2 Inhibitors in Heart Transplant Recipients
Conditions: Transplant; Failure, Heart; Cardiac Allograft Vasculopathy; Rejection Heart Transplant Interventions: Drug: SGLT2i Sponsors: Universidade Federal do Ceara; Hospital de Messejana Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 27, 2023 Category: Research Source Type: clinical trials
Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients
Conditions: Type 2 Diabetes Mellitus Interventions: Drug: SGLT2 inhibitor Sponsors: Jeil Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 22, 2023 Category: Research Source Type: clinical trials
SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning
Conditions: Heart Failure Acute; Ventilator Lung Interventions: Drug: SGLT2 inhibitor Sponsors: National Taiwan University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 21, 2023 Category: Research Source Type: clinical trials
Investigation of Biomarker Response to SGLT2 Inhibition in Heart Failure
Conditions: Heart Failure Interventions: Drug: Sodium-glucose cotransporter 2 inhibitor Sponsors: Queen ' s University, Belfast; Belfast Health and Social Care Trust Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2023 Category: Research Source Type: clinical trials
Effect of Sodium Glucose Cotransporter 2 Inhibitiors on Left Ventricular Remodeling Among Diabetic and Non Diabetic Patients With Chronic Heart Failure
Conditions: SGLT2 Inhibitiors Remodeling Effect; Chronic Heart Disease Interventions: Drug: Sodium-glucose cotransporter 2 inhibitor Sponsors: Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials
The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD)
Conditions: Coronary Artery Disease Interventions: Drug: Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor Sponsors: Clinical Research Centre, Malaysia; University of Malaya; Ministry of Health, Malaysia Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 13, 2023 Category: Research Source Type: clinical trials
SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot
Conditions: Acute Kidney Injury Interventions: Drug: SGLT2 inhibitor Sponsors: University of Minnesota Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials
Zibotentan/Dapagliflozin Combination Demonstrated Significant Albuminuria Reduction in Patients with Chronic Kidney Disease and Proteinuria in ZENITH-CKD Phase IIb Trial
52.5% reduction with high-dose and 47.7% reduction with low-dose combination compared to baseline, and an acceptable tolerability profile
Novel investigational drug leverages SGLT2 inhibition and high selectivity ETA receptor antagonism with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 3, 2023 Category: Pharmaceuticals Source Type: clinical trials
The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus
Conditions: Fatty Liver, Nonalcoholic Interventions: Drug: SGLT2 inhibitor Sponsors: Sohag University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 3, 2023 Category: Research Source Type: clinical trials
Gliflozins on HF in Regurgitant Rheumatic Heart
Conditions: Rheumatic Heart Disease; Heart Failure Interventions: Drug: SGLT2 inhibitor Sponsors: Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 24, 2023 Category: Research Source Type: clinical trials
Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study
Conditions: Chronic Kidney Diseases; Diabetes Mellitus; PreDiabetes; Overweight and Obesity Interventions: Behavioral: Therapeutic carbohydrate restriction combined with an SGLT-2-Inhibitor Sponsors: Department of Nephrology Clinic Ottakring Vienna Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 23, 2023 Category: Research Source Type: clinical trials
The Effect of Addition of Metformin to SGLT2 In Diabetic Patients With Heart Failure With Preserved Ejection Fraction
Conditions: Heart Failure With Preserved Ejection Fraction; Diabete Type 2 Interventions: Drug: Metformin Sponsors: October University for Modern Sciences and Arts; clinical research unit, El-sheikh zayed specialized hospital - Egyptian Ministry of health Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 12, 2023 Category: Research Source Type: clinical trials
